[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Vietnam Tuberculosis Therapeutics Market, By Disease Type (Active Tuberculosis and Latent Tuberculosis), By Therapy (First Line Therapy and Second Line Therapy), By Region, Competition, Forecast and Opportunities, 2019-2029F

June 2024 | 81 pages | ID: V21D49585664EN
TechSci Research

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Vietnam Tuberculosis Therapeutics Market was valued at USD 25.48 Million in 2023 and is anticipated t%li%project impressive growth in the forecast period with a CAGR of 4.12% through 2029. The Vietnam Tuberculosis Therapeutics Market is primarily driven by several key factors contributing t%li%the country's efforts in combating tuberculosis (TB). Government initiatives and healthcare programs aimed at TB prevention, diagnosis, and treatment play a crucial role in driving market growth. Increased funding for TB control programs, coupled with awareness campaigns and improved healthcare infrastructure, enhances access t%li%TB therapeutics across the country. Advancements in medical technology and diagnostic tools facilitate early detection and accurate diagnosis of TB cases, leading t%li%prompt initiation of treatment. Collaborations between government agencies, non-governmental organizations, and pharmaceutical companies contribute t%li%the development and distribution of innovative TB therapeutics. As Vietnam continues t%li%prioritize TB control and eradication efforts, the demand for effective therapeutics is expected t%li%remain high, driving growth in the Vietnam Tuberculosis Therapeutics Market.

Key Market Drivers

Government Initiatives and Healthcare Programs

The Vietnam Tuberculosis Therapeutics Market is significantly influenced by government-led initiatives and healthcare programs aimed at combating tuberculosis (TB) within the country. The Vietnamese government has prioritized TB control efforts, allocating substantial funds towards prevention, diagnosis, and treatment programs. These initiatives include the implementation of national TB control strategies, establishment of TB treatment centers, and provision of subsidized or free TB medications t%li%patients. Government-led campaigns als%li%focus on raising awareness about TB, promoting early detection, and ensuring adherence t%li%treatment protocols, thereby driving the demand for TB therapeutics.

Increasing Prevalence of Tuberculosis

The rising prevalence of TB cases in Vietnam serves as a major driver for the growth of the Tuberculosis Therapeutics Market. Despite significant progress in TB control efforts, Vietnam continues t%li%grapple with a high burden of TB, particularly among vulnerable populations such as those living in impoverished communities, urban slums, and remote rural areas. Factors contributing t%li%the increasing prevalence of TB include overcrowded living conditions, poor sanitation, inadequate healthcare access, and the emergence of drug-resistant TB strains. As the incidence of TB cases continues t%li%rise, there is a corresponding demand for effective therapeutics t%li%treat and manage the disease.

Advancements in Medical Technology

Technological advancements in medical diagnostics and treatment modalities are driving innovation in TB therapeutics in Vietnam. The introduction of rapid molecular diagnostic tests, such as GeneXpert MTB/RIF, has revolutionized TB diagnosis by enabling quick and accurate detection of TB and drug-resistant strains. Advancements in drug development have led t%li%the discovery of new anti-TB medications with improved efficacy, safety profiles, and shorter treatment durations. Innovative treatment regimens, including fixed-dose combinations and shorter-course therapies, enhance patient compliance and treatment outcomes. These advancements contribute t%li%the expansion of the Tuberculosis Therapeutics Market in Vietnam by providing healthcare providers with more effective tools t%li%combat TB.

Growing Awareness and Screening Programs

Increasing awareness about TB and the importance of early detection through screening programs drive demand for TB therapeutics in Vietnam. Public health campaigns, educational initiatives, and community outreach programs aim t%li%educate the public about TB transmission, symptoms, and treatment options. As a result, more individuals seek medical care and underg%li%TB screening tests, leading t%li%early diagnosis and initiation of treatment. Targeted screening programs focus on high-risk populations, such as healthcare workers, prisoners, and individuals living with HIV/AIDS, further contributing t%li%the demand for TB therapeutics.

Emergence of Drug-Resistant TB Strains

The emergence of drug-resistant TB strains, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), drives the demand for specialized TB therapeutics in Vietnam. Conventional TB treatment regimens are often ineffective against drug-resistant strains, necessitating the use of second-line and third-line medications that are more potent and targeted. The prevalence of drug-resistant TB underscores the importance of timely diagnosis, appropriate treatment selection, and adherence t%li%treatment protocols t%li%prevent the spread of resistant strains and improve patient outcomes. Consequently, there is a growing demand for advanced TB therapeutics capable of effectively treating drug-resistant TB cases in Vietnam.

Key Market Challenges

Drug Resistance and Treatment Complexity

One of the significant challenges facing the Vietnam Tuberculosis Therapeutics Market is the emergence of drug-resistant strains of tuberculosis (TB), including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). These drug-resistant strains pose a formidable obstacle t%li%TB treatment, as they are less susceptible t%li%conventional first-line medications, such as isoniazid and rifampicin. Treating drug-resistant TB requires the use of second-line and third-line drugs, which are often more expensive, less effective, and associated with greater toxicity and side effects. Managing drug-resistant TB cases necessitates prolonged treatment durations, close monitoring of patient response, and adherence t%li%complex treatment regimens, increasing the burden on healthcare providers and patients alike. Addressing the challenge of drug-resistant TB requires concerted efforts t%li%improve TB diagnostics, expand access t%li%specialized TB medications, and strengthen infection control measures t%li%prevent the spread of resistant strains within communities.

Limited Access t%li%Diagnostic Services

Access t%li%timely and accurate TB diagnostics remains a significant challenge in Vietnam, particularly in remote and underserved areas where healthcare infrastructure is limited. Diagnostic tools such as sputum microscopy, chest X-rays, and molecular tests like GeneXpert MTB/RIF are essential for detecting TB infections and drug resistance, yet they may not be readily available or accessible t%li%all populations. Limited access t%li%diagnostic services delays the diagnosis of TB cases, leading t%li%delays in treatment initiation and increased transmission of the disease within communities. The lack of trained healthcare personnel and laboratory facilities capable of performing TB diagnostics further compounds the problem. Addressing this challenge requires investments in expanding diagnostic infrastructure, training healthcare workers in TB diagnosis and management, and implementing innovative strategies such as point-of-care testing and mobile health technologies t%li%reach underserved populations.

Key Market Trends

Urbanization and Population Growth

Urbanization and population growth contribute t%li%the increasing burden of TB in urban centers and densely populated areas of Vietnam. Rapid urbanization leads t%li%overcrowding, inadequate housing conditions, and limited access t%li%healthcare services, creating conducive environments for TB transmission. Population growth exacerbates existing healthcare challenges, placing additional strain on healthcare infrastructure and resources. As urban populations expand, s%li%does the demand for TB therapeutics t%li%address the growing incidence of TB cases in urban settings. The Tuberculosis Therapeutics Market in Vietnam responds t%li%these demographic trends by supplying the necessary medications and resources t%li%meet the healthcare needs of urban populations.

International Collaboration and Partnerships

International collaboration and partnerships play a significant role in driving the Tuberculosis Therapeutics Market in Vietnam. Collaborative efforts between the Vietnamese government, international organizations, non-governmental organizations (NGOs), and pharmaceutical companies facilitate the exchange of knowledge, expertise, and resources for TB control and treatment. International donors provide funding, technical assistance, and capacity-building support t%li%strengthen Vietnam's TB control programs and enhance healthcare infrastructure. Partnerships with research institutions and academic centers facilitate clinical trials, drug development, and technology transfer, leading t%li%the introduction of new and improved TB therapeutics in the Vietnamese market.

Segmental Insights

Therapy Insights

Based on the Therapy segment, First Line Therapy currently dominates due t%li%several key factors influencing the country's TB treatment landscape. First Line Therapy refers t%li%the initial standard treatment regimen recommended by the World Health Organization (WHO) for drug-susceptible TB cases. This regimen typically consists of a combination of antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol, administered over a period of six t%li%nine months.

One of the primary reasons for the dominance of First Line Therapy in the Vietnam Tuberculosis Therapeutics Market is its effectiveness and cost-efficiency in treating the majority of TB cases. First Line Therapy has been extensively studied and proven t%li%be highly effective in curing drug-susceptible TB when administered correctly and adhered t%li%by patients. These medications are widely available, affordable, and included in the standard treatment protocols implemented by the National TB Control Program in Vietnam. The majority of TB cases diagnosed in Vietnam are drug-susceptible, meaning they are susceptible t%li%the antibiotics used in First Line Therapy. Drug-susceptible TB comprises the largest proportion of TB cases globally, including in Vietnam, where multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) represent a smaller subset of cases. As a result, First Line Therapy remains the cornerstone of TB treatment in Vietnam, with the majority of patients receiving this regimen upon diagnosis.

Regional Insights

The dominance of the South region in the Vietnam Tuberculosis Therapeutics Market can be attributed t%li%several key factors that contribute t%li%its prominence in addressing the country's TB burden. The South region, encompassing major urban centers such as H%li%Chi Minh City, has a higher population density compared t%li%other regions, leading t%li%a greater concentration of TB cases and healthcare facilities. This increased population density results in a higher demand for TB diagnostics, treatments, and preventive measures, driving market growth in the region.

The South region benefits from better healthcare infrastructure and access t%li%medical resources compared t%li%rural and remote areas, facilitating timely diagnosis and treatment of TB cases. Major cities in the South are equipped with well-established healthcare facilities, including hospitals, clinics, and specialized TB treatment centers, where patients can access quality TB care and therapeutics. The presence of leading medical institutions, research centers, and academic institutions in the South fosters innovation and collaboration in TB treatment and control efforts, further strengthening the region's position in the TB therapeutics market.

The South region serves as a hub for international collaborations, donor-funded projects, and public health initiatives aimed at TB control and prevention. Partnerships between government agencies, non-governmental organizations, and international stakeholders contribute t%li%the implementation of comprehensive TB control programs, capacity-building initiatives, and the distribution of essential TB medications and supplies in the South region. These collaborative efforts enhance access t%li%TB therapeutics and support the region's dominance in the Vietnam Tuberculosis Therapeutics Market.

Key Market Players
  • Novartis Vietnam Company Limited
  • Otsuka Pharmaceutical Vietnam JSC
  • GSK Pharma Viet Nam Company Limited
  • Nam Ha Pharmaceutical Joint Stock Company
  • DHG Pharmaceutical Joint Stock Company
    • Traphac%li%Joint Stock Company
  • Ha Tay Pharmaceutical Joint Stock Company
  • Vietnam Pharmaceutical Corporation
    • Medipharc%li%Pharmaceutical Joint Stock Company
  • OPC Pharmaceutical Joint Stock Company
Report Scope:

In this report, the Vietnam Tuberculosis Therapeutics Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
  • Vietnam Tuberculosis Therapeutics Market, By Disease Type:
  • Active Tuberculosis
  • Latent Tuberculosis
  • Vietnam Tuberculosis Therapeutics Market, By Therapy:
  • First Line Therapy
  • Second Line Therapy
  • Vietnam Tuberculosis Therapeutics Market, By Region:
  • South Vietnam
  • North Vietnam
  • Central Vietnam
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Vietnam Tuberculosis Therapeutics Market.

Available Customizations:

Vietnam Tuberculosis Therapeutics Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:

Company Information
    • Detailed analysis and profiling of additional market players (up t%li%five).

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations


2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations


3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends



5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Disease Type (Active Tuberculosis and Latent Tuberculosis)
  5.2.2. By Therapy (First Line Therapy and Second Line Therapy)
  5.2.3. By Region (Northern, Southern, Central)
  5.2.4. By Company (2023)
5.3. Market Map


6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Disease Type
  6.2.2. By Therapy


7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Disease Type
  7.2.2. By Therapy


8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Disease Type
  8.2.2. By Therapy


9.1. Drivers
9.2. Challenges


10.1. Merger & Acquisition (If Any)
10.2. Product Launches (If Any)
10.3. Recent Developments





14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products


15.1. Novartis Vietnam Company Limited
  15.1.1. Business Overview
  15.1.2. Company Snapshot
  15.1.3. Products & Services
  15.1.4. Financials (As Reported)
  15.1.5. Recent Developments
  15.1.6. Key Personnel Details
  15.1.7. SWOT Analysis
15.2. Otsuka Pharmaceutical Vietnam JSC
15.3. GSK Pharma Viet Nam Company Limited
15.4. Nam Ha Pharmaceutical Joint Stock Company
15.5. DHG Pharmaceutical Joint Stock Company
15.6. Traphaco Joint Stock Company
15.7. Ha Tay Pharmaceutical Joint Stock Company
15.8. Vietnam Pharmaceutical Corporation
15.9. Medipharco Pharmaceutical Joint Stock Company
15.10. OPC Pharmaceutical Joint Stock Company



More Publications